MX2021000805A - Soluciones de complejos de radionuclidos estables y concentradas. - Google Patents

Soluciones de complejos de radionuclidos estables y concentradas.

Info

Publication number
MX2021000805A
MX2021000805A MX2021000805A MX2021000805A MX2021000805A MX 2021000805 A MX2021000805 A MX 2021000805A MX 2021000805 A MX2021000805 A MX 2021000805A MX 2021000805 A MX2021000805 A MX 2021000805A MX 2021000805 A MX2021000805 A MX 2021000805A
Authority
MX
Mexico
Prior art keywords
complex solutions
stable
radionuclide complex
drug product
concentrated
Prior art date
Application number
MX2021000805A
Other languages
English (en)
Inventor
Lorenza Fugazza
Daniela Chicco
Donato Barbato
Palo Francesco De
Maurizio Mariani
Giovanni Tesoriere
Clementina Brambati
Original Assignee
Advanced Accelerator Applications Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/045,484 external-priority patent/US20200030465A1/en
Priority claimed from PCT/IB2018/055575 external-priority patent/WO2020021310A1/en
Application filed by Advanced Accelerator Applications Sa filed Critical Advanced Accelerator Applications Sa
Publication of MX2021000805A publication Critical patent/MX2021000805A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

La presente invención se refiere a soluciones de complejos de radionúclidos de alta concentración y de alta estabilidad química, que permiten su uso como producto farmacéutico para fines de diagnóstico y/o terapéuticos. La estabilidad del producto farmacéutico se logra mediante por lo menos un estabilizador contra la degradación radiolítica. Se encontró que el uso de dos estabilizadores introducidos durante el proceso de fabricación en diferentes etapas fue una ventaja particular.
MX2021000805A 2018-07-25 2018-09-25 Soluciones de complejos de radionuclidos estables y concentradas. MX2021000805A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/045,484 US20200030465A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
PCT/IB2018/055575 WO2020021310A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
PCT/IB2018/057415 WO2020021322A1 (en) 2018-07-25 2018-09-25 Stable, concentrated radionuclide complex solutions

Publications (1)

Publication Number Publication Date
MX2021000805A true MX2021000805A (es) 2021-05-12

Family

ID=63794577

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000805A MX2021000805A (es) 2018-07-25 2018-09-25 Soluciones de complejos de radionuclidos estables y concentradas.

Country Status (13)

Country Link
EP (1) EP3826686A1 (es)
JP (2) JP7402218B2 (es)
KR (2) KR102643582B1 (es)
CN (1) CN112584875A (es)
AU (3) AU2018433575B2 (es)
BR (1) BR112021001148A2 (es)
CA (1) CA3153630A1 (es)
CO (1) CO2021000506A2 (es)
DE (1) DE202018006567U1 (es)
IL (1) IL280314A (es)
MX (1) MX2021000805A (es)
SG (1) SG11202100645XA (es)
WO (1) WO2020021322A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
WO2023100852A1 (ja) * 2021-11-30 2023-06-08 日本メジフィジックス株式会社 安定化放射性医薬組成物
WO2023148680A1 (en) * 2022-02-04 2023-08-10 Advanced Accelerator Applications Methods for large scale synthesis of radionuclide complexes
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
HUP0104693A3 (en) 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors
EE05450B1 (et) 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
IL162734A0 (en) 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
PL221491B1 (pl) 2002-03-08 2016-04-29 Eisai R&D Man Co Związki makrocykliczne, środek farmaceutyczny zawierający te związki oraz zastosowanie tych związków
PL401637A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
WO2005009393A2 (en) * 2003-07-24 2005-02-03 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for preparation
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide
WO2018081860A1 (en) * 2016-11-04 2018-05-11 Clarity Pharmaceuticals Pty Ltd Formulations for radiotherapy and diagnostic imaging

Also Published As

Publication number Publication date
AU2024201217A1 (en) 2024-03-14
JP7402218B2 (ja) 2023-12-20
AU2018433575A1 (en) 2021-02-11
IL280314A (en) 2021-03-25
CA3153630A1 (en) 2020-01-30
KR102643582B1 (ko) 2024-03-05
CN112584875A (zh) 2021-03-30
AU2022203683B2 (en) 2023-12-21
WO2020021322A1 (en) 2020-01-30
AU2022203683A1 (en) 2022-06-16
EP3826686A1 (en) 2021-06-02
BR112021001148A2 (pt) 2021-04-20
JP2022501313A (ja) 2022-01-06
DE202018006567U1 (de) 2021-02-22
CO2021000506A2 (es) 2021-04-19
AU2018433575B2 (en) 2022-07-07
KR20210035855A (ko) 2021-04-01
KR20240033296A (ko) 2024-03-12
SG11202100645XA (en) 2021-02-25
JP2023117417A (ja) 2023-08-23

Similar Documents

Publication Publication Date Title
MX2021000805A (es) Soluciones de complejos de radionuclidos estables y concentradas.
PH12020500509A1 (en) Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
PH12017501921A1 (en) Novel compounds
PL412787A1 (pl) Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
TN2017000452A1 (en) Compositions of obeticholic acid and methods of use
MX2017012131A (es) Composiciones y métodos para la administración de agentes de biomacromoléculas.
PH12017502201A1 (en) Substituted pyridines and method of use
MX2017000980A (es) Composiciones de tratamiento.
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
MX2017000979A (es) Composiciones de tratamiento para el cuidado de las telas y el hogar.
PH12018500690A1 (en) Novel insulin analogs and use thereof
MX2017000978A (es) Composiciones de tratamiento para el cuidado de las telas y el hogar.
MX2016013154A (es) Composicion que contiene peroxido y acido peracetico y proceso para matar esporas.
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
AR100618A1 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA202090270A1 (ru) Новые замещенные производные ксантина
MY172656A (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MY194135A (en) Treatment and diagnosis of inflammatory disorders
MX2017012110A (es) Forma cristalina de ahu377, metodo de preparacion y uso de la misma.
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
MX2020006173A (es) Derivados glucosidicos de treprostinilo.
CO2017003313A2 (es) Un proceso para la producción de complejos de caseína n-acetil-aspartilada de hierro (iii) y uso del mismo en com-posiciones farmacéuticas